<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565330</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-A03</org_study_id>
    <nct_id>NCT01565330</nct_id>
  </id_info>
  <brief_title>A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers</brief_title>
  <official_title>An Open Label, Parallel Group, Dose Comparison of Safety and Imaging Characteristics of 111 and 370 MBq (3 and 10 mCi) of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Patients With Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test two different doses of florbetapir F 18 to determine which dose is best
      to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron
      emission tomography (PET) scanner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Florbetapir-PET Scan Quality</measure>
    <time_frame>0-90 min after injection</time_frame>
    <description>Visual evaluation of image quality by nuclear medicine specialist blinded to dose and clinical information; reported on a 5-point scale (5=excellent and 1=poor).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Cortical to Cerebellum SUVR</measure>
    <time_frame>0-90 min after injection</time_frame>
    <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>111 MBq (3 mCi) AD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>111 MBq (3 mCi) Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>370 MBq (10 mCi) AD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>370 MBq (10 mCi) Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <description>single dose IV injection</description>
    <arm_group_label>111 MBq (3 mCi) AD Group</arm_group_label>
    <arm_group_label>111 MBq (3 mCi) Control Group</arm_group_label>
    <arm_group_label>370 MBq (10 mCi) AD Group</arm_group_label>
    <arm_group_label>370 MBq (10 mCi) Control Group</arm_group_label>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (AD group):

          -  Greater than 50 years of age

          -  Probable AD according to the National Institute of Neurological and Communication
             Disorders and Stroke-Alzheimer's Disease and Related Disorders Association
             (NINCDS-ADRDA) criteria

          -  Mild/moderate dementia as evidenced by a Mini-Mental State Examination (MMSE) score
             ranging from 10 to 24, boundaries included, at screening

          -  History of cognitive decline gradual in onset and progressive over a period of at
             least 6 months

        Inclusion Criteria (healthy volunteer group):

          -  35 to 55 years of age, inclusive

          -  MMSE of 29 or greater

        Exclusion Criteria (both groups):

          -  Neurodegenerative disorders other than AD, including, but not limited to Parkinson's
             disease, Pick's disease, fronto-temporal dementia, Huntington's chorea, Down syndrome,
             Creutzfeldt-Jacob disease, normal pressure hydrocephalus, and progressive supranuclear
             palsy

          -  Diagnosis of other dementing / neurodegenerative disease

          -  Diagnosis of mixed dementia

          -  Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain
             infection, brain cancer, endocrine disease, or mental retardation

          -  Clinically significant infarct or possible multi-infarct dementia as defined by the
             NINCDS criteria

          -  Evidence on screening MRI or other biomarker that suggests alternate etiology for
             cognitive deficit (for healthy controls, evidence suggesting the presence of AD
             pathology)

          -  Clinically significant psychiatric disease

          -  History of epilepsy or convulsions

          -  Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances

          -  Current clinically significant cardiovascular disease

          -  Received investigational medication within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North East</city>
        <state>Maryland</state>
        <zip>21901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <results_first_submitted>April 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>18F-AV-45</keyword>
  <keyword>florbetapir F 18</keyword>
  <keyword>Diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>111 MBq (3 mCi) AD Group</title>
          <description>Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
        </group>
        <group group_id="P2">
          <title>111 MBq (3 mCi) Control Group</title>
          <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="P3">
          <title>370 MBq (10 mCi) AD Group</title>
          <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="P4">
          <title>370 MBq (10 mCi) Control Group</title>
          <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>111 MBq (3 mCi) AD Group</title>
          <description>Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
        </group>
        <group group_id="B2">
          <title>111 MBq (3 mCi) Control Group</title>
          <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="B3">
          <title>370 MBq (10 mCi) AD Group</title>
          <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="B4">
          <title>370 MBq (10 mCi) Control Group</title>
          <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="11.01"/>
                    <measurement group_id="B2" value="48.0" spread="6.73"/>
                    <measurement group_id="B3" value="76.8" spread="10.24"/>
                    <measurement group_id="B4" value="45.0" spread="6.88"/>
                    <measurement group_id="B5" value="59.4" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Florbetapir-PET Scan Quality</title>
        <description>Visual evaluation of image quality by nuclear medicine specialist blinded to dose and clinical information; reported on a 5-point scale (5=excellent and 1=poor).</description>
        <time_frame>0-90 min after injection</time_frame>
        <population>One subject in the 370 MBq (10 mCi) AD Group did not complete all imaging time periods</population>
        <group_list>
          <group group_id="O1">
            <title>111 MBq (3 mCi) AD Group</title>
            <description>Subjects with Alzheimer's Disease (AD) who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
          </group>
          <group group_id="O2">
            <title>111 MBq (3 mCi) Control Group</title>
            <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
          </group>
          <group group_id="O3">
            <title>370 MBq (10 mCi) AD Group</title>
            <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
          </group>
          <group group_id="O4">
            <title>370 MBq (10 mCi) Control Group</title>
            <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18</description>
          </group>
        </group_list>
        <measure>
          <title>Florbetapir-PET Scan Quality</title>
          <description>Visual evaluation of image quality by nuclear medicine specialist blinded to dose and clinical information; reported on a 5-point scale (5=excellent and 1=poor).</description>
          <population>One subject in the 370 MBq (10 mCi) AD Group did not complete all imaging time periods</population>
          <units>florbetapir scans</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cortical to Cerebellum SUVR</title>
        <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
        <time_frame>0-90 min after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>111 MBq (3 mCi) AD Group</title>
            <description>Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
          </group>
          <group group_id="O2">
            <title>111 MBq (3 mCi) Control Group</title>
            <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
          </group>
          <group group_id="O3">
            <title>370 MBq (10 mCi) AD Group</title>
            <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
          </group>
          <group group_id="O4">
            <title>370 MBq (10 mCi) Control Group</title>
            <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cortical to Cerebellum SUVR</title>
          <description>Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum.</description>
          <units>SUVR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.781" spread="0.217"/>
                    <measurement group_id="O2" value="0.968" spread="0.050"/>
                    <measurement group_id="O3" value="1.658" spread="0.288"/>
                    <measurement group_id="O4" value="0.988" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs reported within 7 days of injection; SAEs reported within 30 days of injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>111 MBq (3 mCi) AD Group</title>
          <description>Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel</description>
        </group>
        <group group_id="E2">
          <title>111 MBq (3 mCi) Control Group</title>
          <description>Healthy controls who received 111MBq (3 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="E3">
          <title>370 MBq (10 mCi) AD Group</title>
          <description>Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
        <group group_id="E4">
          <title>370 MBq (10 mCi) Control Group</title>
          <description>Healthy controls who received 370MBq (10 mCi) of florbetapir F 18</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE IRRITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-290-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

